Tempus

This fall, leaders from Tempus and @RecursionPharma came together for a webinar to explore their strategic TechBio partnership. Sid Jain, Hayley Donnella, Ph.D., and Shane Woods, Ph.D. discussed they use #AI and supercomputing with petabytes of data to accelerate drug discovery and development. Access the full recording to hear the impact on biopharma R&D's future: tempus.co/4spmOdC

Join us for a live session exploring how foundation models move beyond single-purpose #AI to answer broader, more complex biological observations. Attendees will also learn more about our unique pathway from building a proof-of-concept model to deploying it directly into the clinic. Register here: tempus.co/4sfvenI

Join us at @TheUSCAP Annual Meeting to explore our comprehensive pathology offerings and latest research. Combining Paige’s industry-leading digital pathology expertise with the broader Tempus ecosystem, we are redefining what’s possible in AI-enabled pathology to empower anatomic and molecular pathologists worldwide. #USCAP2026 Head to booth #542 and learn more here: tempus.co/40H00K5

A new case study details the significant, quantifiable improvements two community-based sites have seen across their research programs since joining the TIME network. Read now: tempus.co/4sgD8Nw

We're thrilled to announce a strategic collaboration with @BloodCancerUtd to develop a comprehensive, patient-centered, real-world registry for pediatric acute myeloid leukemia (pAML), a rare and aggressive blood cancer. Learn more: tempus.co/4sVBPnr

Traditional preclinical models, from 2D cell lines to animal models, have long struggled to capture the profound heterogeneity and biological complexity of human cancer. To move beyond linear, siloed research, Tempus is building an integrated engine for discovery and validation. Learn more in a new article here: tempus.co/3P877Zu

A new study published in @JCOPO_ASCO shows how advanced features of comprehensive genomic profiling expand treatment options for cancer patients in community oncology settings. In the study, 12% (approximately 1 in 8) of patients across the pilot and expanded cohorts had potentially actionable findings associated with an approved therapy identified solely through advanced Tempus features—such as tumor-normal matching, RNA sequencing, and liquid biopsy reflex testing—that would otherwise have been missed by less comprehensive tests. Learn more: tempus.co/4ljaPLK

Join us for an upcoming webinar to learn more about how multimodal data informs critical decisions across the R&D lifecycle. Industry leaders, Dave Lennon, Kyle Kai-How Farh MD PhD, Philip Perez, and Martin Bontrager will be discussing how to validate novel targets and increase the probability of technical success for clinical programs. Register now: tempus.co/4s8aRsA

For life sciences companies, the journey from a promising compound to a first-in-human study is filled with operational hurdles that can delay timelines and inflate cost. A new case study details how sponsors are leveraging the Tempus TIME Trial Network to launch Phase 1 studies more efficiently, reaching critical milestones faster. Read here: tempus.co/3NaqtMR

Tempus researchers used real-world data in Lens to explore how specific KRAS variants impact treatment outcomes in colorectal cancer. The analysis revealed that while patients with different KRAS variants showed no survival differences when treated with first-line anti-VEGF therapy plus chemotherapy, those with KRAS mutations overall had reduced survival compared to KRAS-WT. These results underscore the importance of considering specific KRAS variants when personalizing treatment strategies. Explore the full study in the Lens Library now: tempus.co/4rSSZBY

Today, we announced a multi-year strategic collaboration with @Merck. “We are thrilled to be working with Merck as our newest strategic partner, joining others that have committed to long-term data licenses, including AZ, GSK, and BMS. Together, we share a dedication to bringing the benefits of AI to drug discovery and development." - Tempus CEO and Founder, @lefkofsky Read on: tempus.co/4aOAwAk

This Colorectal Cancer Awareness Month, we recognize the commitment it takes to manage the complexity of #CRC. At Tempus, we believe every patient’s journey is unique and we’re committed to delivering the molecular insights needed to support personalized care at every stage. Our comprehensive portfolio provides a 360-degree view of your patient’s disease, from informing treatment selection to monitoring for recurrence and response with our MRD portfolio. Learn more about our solutions for colorectal cancer: tempus.co/4bnMIHx

We're looking forward to attending @PMWCintl next week. Join @LaurenRSilvis and @EzraCohen for their live sessions, or visit our team at Booth #A509 to learn more about how we are leading the adoption of #AI to advance precision medicine and patient care. #PMWC26

Clinical laboratories are using artificial intelligence (AI), machine learning, and advanced diagnostics to power precision medicine and improve patient outcomes. Hear from Dr. Kate Sasser, CSO of @Tempus, on how data and technology are transforming #ThePowerofKnowing.

Paul Fields recently hosted an interactive discussion centered on how to leverage Tempus’ specialized datasets to accelerate discovery. Key takeaways from this engaging session include: 🔬 Integrating multimodal data with patient-derived organoids provides a powerful method for identifying and validating novel drug targets. 📈 Applying real-world data throughout the drug development lifecycle helps optimize trial design, validate biomarker strategies, and reduce clinical program risk. 💡 Tempus’ Immune Profile Score (IPS), an AI-developed algorithm providing prognostic insights into rwOS, can be rapidly analyzed within the Tempus Lens platform to uncover prognostic insights. Access the full recording here: tempus.co/4tLXek1

Applications for our Summer Associate program are now open. These rules range from Strategy & Ops to Software Engineering and Applied AI Research. Learn more and apply here: tempus.co/summerprogram

Our CEO Eric Lefkofsky and our CFO Jim Rogers share more context on how we view those results in a quarterly letter you can read here: investors.tempus.com/static-files/b…

Today we shared fourth quarter and full year 2025 financial results. Find the full report here: tempus.co/4795a53